Trevena, Inc. (NASDAQ:TRVN) Q3 2023 Earnings Call Transcript

Carrie Bourdow: Yes, great question. No, no, it’s not a gating item. I think it will add to the story. We’ll see what the data looks like, but I think it is an important part of the story is related to epilepsy, because certainly we are worth, you know, thinking about treatment, but given some of the interesting characteristics of the data that we’ve seen so far, having those seizure prevention data would really help broaden those considerations that we have and frankly the conversations that we’re having with partners. But it is not a gating factor. It’ll just add to the overall story for TRV045.

Douglas Tsao: And Carrie, could you envision a scenario where you have partners for epilepsy and a different partner for pain? Or are you generally looking for somebody who would be able to help, you know, support the program across all indications? Thank you.

Carrie Bourdow: Yes, yes. So Probably not. Well, not in the first part, in that we would have a scenario where we would have different partners in pain. There are, of course, as you might imagine, different partners currently that are interested in either pain or epilepsy, but there are, you know, partners that are also interested in both given how interesting this data set is. So we would choose a path as it relates to moving forward. And some of that is also of course, Doug, as we’ve talked in the past around the commercial assessment, right? The pricing models are different in pain versus epilepsy, how you think about the indications of development program forward. But it’s certainly terrific right now to have these choices in front of us.

Douglas Tsao: Okay, great. Thank you.

Operator: Thank you. There are no further questions at this time. I would now like to turn the floor over to Carrie Bourdow for closing comments.

Carrie Bourdow: Great. Thank you, Operator. And thank you, everyone, for joining the call today. As you heard from Mark, we’re actively advancing TRV045, working to optimize the formulation and on our toxicology studies with the expected completion in the second-half of next year. We’re also continuing to talk with interested strategic partners in both epilepsy and pain. And as we said, these are two large markets where a novel mechanism of action like TRV045 can potentially have a significant impact. So we look forward to providing you with additional updates on our progress, and thank you again.

Operator: Thank you. This concludes today’s teleconference. You may disconnect your lines at this time. Thank you for your participation.